Regenxbio Stock Today
| RGNX Stock | USD 9.92 0.09 0.90% |
Performance0 of 100
| Odds Of DistressLess than 42
|
Regenxbio is trading at 9.92 as of the 30th of November 2024; that is 0.9 percent decrease since the beginning of the trading day. The stock's open price was 10.01. Regenxbio has about a 42 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Note, on November 14, 2019, Representative Peter Welch of US Congress acquired under $15k worth of Regenxbio's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 17th of September 2015 | Category Healthcare | Classification Health Care |
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The company has 49.55 M outstanding shares of which 4.62 M shares are at this time shorted by private and institutional investors with about 7.31 trading days to cover. More on Regenxbio
Moving together with Regenxbio Stock
Moving against Regenxbio Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Regenxbio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Kenneth Mills | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRegenxbio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Regenxbio's financial leverage. It provides some insight into what part of Regenxbio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Regenxbio (RGNX) is traded on NASDAQ Exchange in USA. It is located in 9804 Medical Center Drive, Rockville, MD, United States, 20850 and employs 344 people. Regenxbio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 491.49 M. Regenxbio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 49.55 M outstanding shares of which 4.62 M shares are at this time shorted by private and institutional investors with about 7.31 trading days to cover.
Regenxbio currently holds about 402.96 M in cash with (218.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.32.
Check Regenxbio Probability Of Bankruptcy
Ownership AllocationRegenxbio owns a total of 49.55 Million outstanding shares. The majority of Regenxbio outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Regenxbio to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Regenxbio. Please pay attention to any change in the institutional holdings of Regenxbio as this could imply that something significant has changed or is about to change at the company. On November 14, 2019, Representative Peter Welch of US Congress acquired under $15k worth of Regenxbio's common stock.
Check Regenxbio Ownership Details
Regenxbio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Aquilo Capital Management, Llc | 2024-09-30 | 930.7 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 649.2 K | |
| Adar1 Capital Management Llc | 2024-09-30 | 569 K | |
| Assenagon Asset Management Sa | 2024-09-30 | 559.9 K | |
| Northern Trust Corp | 2024-09-30 | 488 K | |
| Charles Schwab Investment Management Inc | 2024-09-30 | 417.7 K | |
| Sonic Gp Llc | 2024-09-30 | 403.1 K | |
| Rtw Investments, Llc | 2024-06-30 | 350 K | |
| Bank Of New York Mellon Corp | 2024-06-30 | 339.5 K | |
| Blackrock Inc | 2024-06-30 | 8.6 M | |
| Redmile Group, Llc | 2024-09-30 | 4.9 M |
Regenxbio Historical Income Statement
Regenxbio Stock Against Markets
Regenxbio Corporate Management
| Ram PharmD | Executive Operations | Profile | |
| JD II | Executive Officer | Profile | |
| Tricia Truehart | VP Communications | Profile | |
| Olivier Danos | Chief Scientific Officer | Profile |
Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.